HARVARD BIOSCIENCE INC
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
HBIO$9.26+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders' Equity
(Unaudited, in thousands)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Number · Additional · Other · Total | ||||||
| of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Issued * | Stock | Capital | Deficit | Loss | Equity | |
| Balance at March 31, 2026 | 4,511 | $447 | $240,046 | $(218,134) | $(12,313) | $10,046 |
| Vesting of restricted stock units | 49 | - | - | - | - | - |
| Shares withheld for taxes | (8) | - | (36) | - | - | (36) |
| Stock-based compensation | - | - | 380 | - | - | 380 |
| Net loss | - | - | - | (2,910) | - | (2,910) |
| Other comprehensive loss | - | - | - | - | (62) | (62) |
| Balance at June 30, 2026 | 4,552 | $447 | $240,390 | $(221,044) | $(12,375) | $7,418 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Number · Additional · Other · Total | ||||||
| of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Issued * | Stock | Capital | Deficit | Loss | Equity | |
| Balance at March 31, 2025 | 4,421 | $442 | $237,104 | $(208,350) | $(14,361) | $14,835 |
| Stock purchase plan | 12 | 1 | 46 | 47 | ||
| Vesting of restricted stock units | 20 | 2 | - | - | - | 2 |
| Shares withheld for taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | 472 | - | - | 472 |
| Net loss | - | - | - | (2,282) | - | (2,282) |
| Other comprehensive income | - | - | - | - | 2,659 | 2,659 |
| Balance at June 30, 2025 | 4,453 | $445 | $237,622 | $(210,632) | $(11,702) | $15,733 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Number · Additional · Other · Total | ||||||
| of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Issued * | Stock | Capital | Deficit | Loss | Equity | |
| Balance at December 31, 2025 | 4,472 | $447 | $239,669 | $(214,710) | $(11,672) | $13,734 |
| Warrant exercises | 30 | - | 150 | - | - | 150 |
| Vesting of restricted stock units | 63 | - | - | - | - | - |
| Shares withheld for taxes | (13) | - | (66) | - | - | (66) |
| Stock-based compensation | - | - | 637 | - | - | 637 |
| Net loss | - | - | - | (6,334) | - | (6,334) |
| Other comprehensive loss | - | - | - | - | (703) | (703) |
| Balance at June 30, 2026 | 4,552 | $447 | $240,390 | $(221,044) | $(12,375) | $7,418 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Number · Additional · Other · Total | ||||||
| of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |
| Issued * | Stock | Capital | Deficit | Loss | Equity | |
| Balance at December 31, 2024 | 4,407 | $441 | $236,579 | $(158,010) | $(15,670) | $63,340 |
| Stock purchase plan | 12 | - | 46 | - | 46 | |
| Vesting of restricted stock units | 44 | 4 | - | - | 4 | |
| Shares withheld for taxes | (10) | - | (75) | - | - | (75) |
| Stock-based compensation | - | - | 1,072 | - | - | 1,072 |
| Net loss | - | - | - | (52,622) | - | (52,622) |
| Other comprehensive income | - | - | - | - | 3,968 | 3,968 |
| Balance at June 30, 2025 | 4,453 | 445 | 237,622 | (210,632) | (11,702) | 15,733 |
| * | Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026. |
|---|
HARVARD BIOSCIENCE, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.